Ching-Yu Chen

Clinical Implications of Using Racemic Drugs

C. Chen, W. Shieh, Ching-Yu Chen, 1992 .

Antitumor Effects of a Novel Phenylbutyrate-Based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer

S. Kulp, Dasheng Wang, Chang‐Shi Chen, 2006, Clinical Cancer Research.

Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation.

Ching-Yu Chen, S. Kulp, S. Matsuyama, 2007, Cancer research.

Development of small-molecule cyclin D1-ablative agents.

Dasheng Wang, Ching-shih Chen, C. Shiau, 2006, Journal of medicinal chemistry.

Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor

Ching-Yu Chen, Charles L. Shapiro, C. Shapiro, 2006, Molecular Pharmacology.

Histone Deacetylase Inhibitors Sensitize Prostate Cancer Cells to Agents that Produce DNA Double-Strand Breaks by Targeting Ku 70 Acetylation

S. Kulp, S. Matsuyama, Yu-Chieh Wang, 2007 .

Metabolic stereoisomeric inversion of ibuprofen in mammals.

C. Y. Chen, S. Harriman, C. S. Chen, 1991, Biochimica et biophysica acta.

Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor

C. Shapiro, Ping-Hui Tseng, S. Dunn, 2006, Molecular Pharmacology.